June 24, 2013 08:00 ET

Actavis Launches Generic Viagra® in Europe as Patents Expire

ZUG, SWITZERLAND--(Marketwired - Jun 24, 2013) - Actavis, Inc. (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has launched Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 major Western-European markets on market formation. Sildenafil Actavis, the generic equivalent of Pfizer's Viagra®, is prescribed to treat erectile dysfunction.

Actavis' product was launched immediately after the patents expired in Austria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain, Sweden, Switzerland and the United Kingdom.

Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - the first generic Sildenafil to enter the patent-free Bulgarian market - and has since launched the product in various other patent-free markets in Europe, including Iceland and Malta. Sildenafil Actavis is manufactured and developed by Actavis, in Malta and Iceland respectively.

According to IMS Health, Viagra® had sales of EUR382.2 million in Europe for the 12 months ending March 31, 2013.

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Parsippany, New Jersey, USA.

Operating as Actavis Pharma, Actavis develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.

Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical business focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing information as of the date of this release. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actual results may differ materially from Actavis' current expectations depending upon a number of factors, risks and uncertainties affecting Actavis' business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental laws, rules and regulations applicable to Actavis and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limiting to Actavis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and Actavis' annual report on Form 10-K for the year ended December 31, 2012. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

Viagra® is a registered trademark of Pfizer, Inc.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Actavis via Thomson Reuters ONE


Contact Information

    Lisa DeFrancesco
    +1 862 261 7152

    Elisabet Hjaltadottir
    +41 79 909 7370